Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glutathione/inosine - BAM

Drug Profile

Glutathione/inosine - BAM

Alternative Names: BAM-205; Inosine glycyl-cysteinyl-glutamate disodium - Pharma VAM; Molixan; NOV-205

Latest Information Update: 28 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BAM
  • Developer BAM; Cellectar Biosciences; North-Western State Medical University
  • Class Anti-inflammatories; Antiasthmatics; Antifibrotics; Antineoplastics; Antivirals; Chemoprotectants; Hepatoprotectants; Oligopeptides; Purine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Immunomodulators; Nerve growth factor stimulants; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B; Hepatitis C
  • Phase III COVID 2019 infections
  • Discontinued Radiation injuries

Most Recent Events

  • 28 Jul 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections(Prevention) in Russia (Inhalation)
  • 09 Mar 2021 Phase-III clinical trials in COVID-2019 infections (In adults, In the elderly) in Russia (IM) (NCT04780672)
  • 09 Mar 2021 Phase-III clinical trials in COVID-2019 infections (In adults, In the elderly) in Russia (IV) (NCT04780672)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top